arrow
B

Bonnie J. Howell

merck & company
H指数:33
被引数:6,470

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TGF-β mediates epigenetic control of innate antiviral responses and SIV reservoir size

TGF-β介导天然抗病毒反应的表观遗传调控和SIV储库大小

2026-03-010
PRE
Comparison of manual and automated ultrasensitive assays for residual HIV-1 in plasma from individuals on suppressive antiretroviral therapy

比较手动和自动化超敏检测法对接受抑制性抗逆转录病毒治疗的个体血浆中残余HIV-1的检测

2025-11-010
PRE
TGF-b mediates epigenetic control of innate antiviral responses and SIV/HIV reservoir size
2025-11-010
PRE
Patient-derived colorectal microtumors predict response to anti-PD-1 therapy

患者来源的结直肠微肿瘤预测抗PD-1疗法的反应

2025-08-120
OA
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption (vol 25, pg 1900, 2024)

IL-10和PD-1的双阻断导致分析性治疗中断后SIV病毒反弹得到控制(卷25,页1900,2024)

2025-01-160
OA
Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption
2024-09-122
OAAI
Initial productive and latent HIV infections originate in vivo by infection of resting T cells
2023-11-152
OAAI
A high-throughput microfluidic mechanoporation platform to enable intracellular delivery of cyclic peptides in cell-based assays

一种高通量微流体机械加工平台,可在基于细胞的测定中实现环肽的细胞内递送

2023-05-131
OAAI
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1
2023-02-2211
PRE
A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected Cells
2022-08-3118
PRE
Detecting Sources of Immune Activation and Viral Rebound in HIV Infection
2022-08-1010
OA
Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo

联合非规范nf-κb激动和靶向BET溴结构域抑制逆转HIV体外潜伏期

2022-04-1518
OAAI
Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy
2022-04-1527
OAAI
Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial
2022-02-1713
OA
Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States
2022-02-079
OAAI